



# CONFERENCE PROGRAMME


**Sunday, 18 October 2015**

<b>09:00-09:10</b>	<b>Opening Remarks: Crystal Ballroom 1&amp;2</b> Publisher of <i>Vaccine</i> Alina Helsen & Congress Co-Chairs Margaret Liu and Ted M. Ross	
<b>09:10-10:40</b>	<b>Opening Session: Crystal Ballroom 1&amp;2</b> Session Chairs: Margaret Liu and Joon Haeng Rhee	Sponsored by 
<b>09:10-09:40</b>	<b>[O1.1] Vaccines and mechanisms of host defense</b> M.K. Slifka, <i>Oregon Health Sciences University, USA</i>	
<b>09:40-10:10</b>	<b>[O1.2] Exploring CD8+ T-cell epitope selection: Implications for immunogen design</b> L.S. Klavinskis, <i>King's College London, UK</i>	
<b>10:10-10:40</b>	<b>[O1.3] Therapeutic HPV 16/18 DNA vaccine, GX-188, induces a high rate of not only clearance of HPV infection, but also regression of cervical intraepithelial neoplasia III</b> Y.C. Sung <sup>1</sup> , H.T. Jin <sup>1</sup> , T.J. Kim <sup>2</sup> , S.Y. Hur <sup>3</sup> , J.S. Park* <sup>3</sup> <sup>1</sup> <i>Pohang University of Science and Technology, Republic of Korea,</i> <sup>2</sup> <i>Kwan Dong Medical University, Republic of Korea,</i> <sup>3</sup> <i>The Catholic University of Korea, Republic of Korea</i>	
<b>10:40-11:00</b>	<b>Refreshment Break Crystal Ballroom Foyer</b>	
<b>11:00-11:30</b>	<b>[O1.4] Multifaceted immunological mechanisms associated with protection in humans following oral vaccination or challenge with wild-type <i>Salmonella typhi</i></b> M. Sztein, <i>University of Maryland, USA</i>	
<b>11:30-12:00</b>	<b>[O1.5] Recent progress in the development of malaria vaccines to reduce morbidity and mortality and accelerate elimination and eradication</b> A.J. Birkett, <i>PATH Malaria Vaccine Initiative (MVI), USA</i>	
<b>12:00-12:30</b>	<b>[O1.6] Development of a recombinant VSV-based Ebola vaccine</b> D. Casimiro, <i>Merck Research Laboratories, USA</i>	
<b>12:30-13:30</b>	<b>Lunch</b> <i>Crystal Ballroom Foyer</i>	Sponsored by 
<b>13:30-15:40</b>	<b>Breakout Session 1: Immunology of Vaccines</b> Session Chairs: Natalie Garcon and Ling Chen <i>Crystal Ballroom 1</i>	<b>Breakout Session 2: Vaccine Design</b> Session Chairs: Annie De Groot and Denise Doolan <i>Crystal Ballroom 2</i>
<b>13:30-13:50</b>	<b>[B1.1] Concomitant loss of neutralizing B cell epitopes and CD4 T cell epitopes in hemagglutinin of drifted influenza viruses</b> R. Powers, J. Kim, J. Jacob*, <i>Emory University, USA</i>	<b>[B2.1] Rational vaccine design against complex pathogens using genomic sequence data</b> D.L. Doolan*, C. Proietti, J. Burel, J. Roddick, A. Trieu, K. de Sousa, S.H. Apte <i>QIMR Berghofer Medical Research Institute, Australia</i>
<b>13:50-14:10</b>	<b>[B1.2] Analysis of antibody repertoire in rhesus macaques after immunization with influenza virus vaccine using NGS and a new sensitive bioluminescent based microneutralization assay</b> L. Chen* <sup>1,2</sup> , X. Niu <sup>2</sup> , C. Li <sup>2</sup> <sup>1</sup> <i>The First Affiliated Hospital of Guangzhou Medical University, China,</i> <sup>2</sup> <i>Chinese Academy of Sciences, China</i>	<b>[B2.2] H7N9 T cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance</b> R.L. Liu* <sup>1</sup> , L.M. Moise <sup>1,2</sup> , R.T. Tasson <sup>1</sup> , A.G. Gutierrez <sup>1</sup> , F.T. Terry <sup>2</sup> , K.S. Sangare <sup>3</sup> , M.A. Ardito <sup>2</sup> , W.M. Martin <sup>2</sup> , A. De Groot <sup>1,2</sup> <sup>1</sup> <i>University of Rhode Island, USA,</i> <sup>2</sup> <i>EpiVax, Inc., USA,</i> <sup>3</sup> <i>University of Bamako, Mali</i>
<b>14:10-14:25</b>	<b>[B1.3] Intrauterine immunization using swine as an animal model</b> J.A. Pasternk <sup>1</sup> , G. Hamonic <sup>1</sup> , T. Käser <sup>1</sup> , M.K. Dyck <sup>2</sup> , V. Gerdt <sup>1</sup> , H.L. Wilson* <sup>1</sup> <sup>1</sup> <i>University of Saskatchewan, Canada,</i> <sup>2</sup> <i>University of Alberta, Canada</i>	<b>[B2.3] Strategic multi-attribute ranking tool for vaccines - SMART Vaccines: informing vaccine decision making</b> S. Knobler* <sup>1</sup> , C. Hoest <sup>1</sup> , K. Bok <sup>2</sup> , M. Miller <sup>1</sup> , B. Gellin <sup>2</sup> <sup>1</sup> <i>National Institutes of Health, USA,</i> <sup>2</sup> <i>United States Department of Health and Human Services, USA</i>
<b>14:25-14:40</b>	<b>[B1.4] Co-delivery of HIV envelope protein in alum with MVA/HIV vaccine induces CXCR3-biased follicular CD4 T cell response in rhesus macaques</b>	<b>[B2.4] A systems biology framework for the identification of the molecular basis of immune adjuvanticity</b> L.P. Trathipati* <sup>1</sup> , T. Aoshi <sup>1,2</sup> , Y. Igarashi <sup>1</sup> , K. Ishii <sup>1,2</sup> ,

	S. Iyer, S. Gangadhara, R. Amara* <i>Emory University, USA</i>	K. Mizuguchi <sup>1</sup> <sup>1</sup> <i>National Institute of Biomedical Innovation (NIBIO), Japan, <sup>2</sup>Osaka University, Japan</i>
14:40-14:55	<b>[B1.5] Biomimetic vaccine formulation for effective antigen presentation and immune activation</b> W. Wei*, D.Z. Ni, H. Yue, G.H. Ma <i>Chinese Academy of Sciences, China</i>	<b>[B2.5] Identifying and exploiting toxin-derived CD4+ T cell epitopes in the design of sub-unit based vaccines against anthrax</b> S. Ascough* <sup>1</sup> , R.J. Ingram <sup>2</sup> , J.A. Musson <sup>3</sup> , M. Doganay <sup>4</sup> , L. Baille <sup>5</sup> , E.D. Williamson <sup>6</sup> , J.H. Robinson <sup>3</sup> , B. Mailere <sup>7</sup> , R.J. Boyton <sup>8</sup> , D.M. Altmann <sup>8</sup> <sup>1</sup> <i>The Pribright Institute, UK, <sup>2</sup>Queen's University, UK, <sup>3</sup>Newcastle University, UK, <sup>4</sup>Erclyes University Hospital, Turkey, <sup>5</sup>Cardiff University, UK, <sup>6</sup>DSTL, UK, <sup>7</sup>CEA, France, <sup>8</sup>Imperial College, UK</i>
14:55-15:10	<b>[B1.6] The activating NKG2D receptor acts as a co-receptor for anti-HIV-1 antibody-dependent cellular cytotoxicity</b> M.S. Parsons* <sup>1</sup> , J. Richard <sup>3</sup> , W.S. Lee <sup>1</sup> , M. Grant <sup>2</sup> , A. Finzi <sup>3</sup> , S.J. Kent <sup>1</sup> <sup>1</sup> <i>University of Melbourne, Australia, <sup>2</sup>Memorial University of Newfoundland, Canada, <sup>3</sup>Universite de Montreal, Canada</i>	<b>[B2.6] Design and Immunological evaluation of chimeric vaccines against <i>B. abortus</i> using SOD, BAB1_0273, BAB1_0278 proteins</b> A. Oñate*, E. Escalona, D. Sáez <i>Universidad de Concepción, Chile</i>
15:10-15:25	<b>[B1.7] Role of CCL5 ligand mediated reproductive homing pathway for Herpes nasal vaccine development</b> S. Joo*, A. Suwanto, A. Sato, S. Sato, Y. Kawaguchi, H. Kiyono, <i>The University of Tokyo, Japan</i>	<b>[B2.7] A systems level analysis of adjuvant transcriptomes for biomarker and target discovery</b> L.P. Tripathi* <sup>1</sup> , J. Ito <sup>1</sup> , T. Aoshi <sup>1,2</sup> , K.J. Ishii <sup>1,2</sup> , K. Mizuguchi <sup>1</sup> <sup>1</sup> <i>National Institutes of Biomedical Innovation, Health &amp; Nutrition, Japan, <sup>2</sup>Osaka University, Japan</i>
15:25-15:40	<b>[B1.8] Exosome targeting DNA vaccination enhances antigen-specific CD8 T cell responses</b> T.K. Kanuma* <sup>1,3</sup> , K.K. Kobiyama <sup>2,3</sup> , K.J.I. Ishii <sup>2,3</sup> <sup>1</sup> <i>Osaka University, Japan, <sup>2</sup>WPI Immunology Frontier Research Center, Japan, <sup>3</sup>National Institutes of Biomedical Innovation, Japan</i>	<b>[B2.8] Crude preparation of bacterially-produced viral subunits as a single-shot avian influenza vaccine</b> N. Wibowo, Y. Wu, Y. Fan, J. Meers, L.H.L. Lua*, A.P.J. Middelberg <i>The University of Queensland, Australia</i>
15:40-16:10	<b>Refreshment Break</b> <i>Crystal Ballroom Foyer</i>	
16:10-18:05	<b>Breakout Session 3: Immunomodulators</b> Supported by Korean Vaccine Society Session Chairs: Jerome Kim and Jun Hee Woo <i>Crystal Ballroom 1</i>	<b>Breakout Session 4: Vaccines for Emerging and Re-Emerging Pathogens and Parasites</b> Session Chairs: David Weiner and Peter Lijeström <i>Crystal Ballroom 2</i>
16:10-16:30	<b>[B3.1] Reposition of GM-CSF as a novel adjuvant for therapeutic vaccine to treat chronic HBV infection</b> B. Wang, <i>Shanghai Medical College and National Engineering Lab for Therapeutic Vaccines, China</i>	<b>[B4.1] The making of a Chikungunya vaccine - comparing attenuated &amp; vectored vaccine platforms</b> P. Liljeström* <sup>1</sup> , P. Roques <sup>2,3</sup> , K. Ljungberg <sup>1</sup> , B.M. Kümmerer <sup>4</sup> , L. Gosse <sup>2,3</sup> , N. Deureddre-Bosquet <sup>2,3</sup> , D. Hallengård <sup>1</sup> , J. García-Arriaza <sup>5</sup> , M. Esteban <sup>5</sup> , A. Merits <sup>6</sup> , R. Le Grand <sup>1</sup> <sup>1</sup> <i>Karolinska Institutet, Sweden, <sup>2</sup>IDMIT infrastructure, France, <sup>3</sup>Center for Immunology of Viral Infections and Autoimmune Diseases, France, <sup>4</sup>University of Bonn Medical Centre, Germany, <sup>5</sup>Consejo Superior de Investigaciones Científicas, Spain, <sup>6</sup>University of Tartu, Estonia</i>
16:30-16:50	<b>[B3.2] Delta inulin (advax<sup>tm</sup>): A new paradigm in vaccine adjuvants</b> N. Petrovsky, <i>Vaxine Pty Ltd, Australia</i>	<b>[B4.2] Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pH1N1 influenza A viruses</b> S.C. Wu, <i>National Tsing Hua University, Taiwan</i>
16:50-17:05	<b>[B3.3] PLGA (85:15) Nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects</b>	<b>[B4.3] A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against</b>

	<p><b>against <i>Brucella abortus</i> 544 infection: A promising alternate to traditional adjuvants</b>  D. Singh*, R. Bhatnagar  <i>Jawahar Lal Nehru University, India</i></p>	<p><b>middle east respiratory syndrome coronavirus in non-human primates</b>  K. Muthumani*<sup>1</sup>, D.B. Weiner<sup>1</sup>, D. Falzarano<sup>2</sup>, E. Reuschel<sup>1</sup>, C. Tingey<sup>1</sup>, S. Flingai<sup>1</sup>, D.O. Villarreal<sup>1</sup>, M. Wise<sup>1</sup>, A. Patel<sup>1</sup>, A. Izmirly<sup>1</sup> <i>et al.</i>  <sup>1</sup><i>University of Pennsylvania School of Medicine, USA,</i>  <sup>2</sup><i>National Institute of Allergy and Infectious Diseases, USA,</i> <sup>3</sup><i>University of Manitoba and Public Health Agency of Canada, USA,</i> <sup>4</sup><i>Inovio Pharmaceuticals Inc., USA,</i> <sup>5</sup><i>NIH, USA,</i> <sup>6</sup><i>University of Washington, USA,</i> <sup>7</sup><i>University of South Florida Morsani College of Medicine, USA</i></p>
17:05-17:20	<p><b>[B3.4] Exploring potent immunological regulation of interferon-inducible 25-hydroxycholesterol as a novel adjuvant for HIV vaccine</b>  C.J. Sun*, T.J. Wu, L. Chen  <i>Guangzhou Institutes of Biomedicine and Health (GIBH), China</i></p>	<p><b>[B4.4] Host immune status and parasite determinates influence the vaccine efficacy against <i>Leishmania</i> parasites</b>  L. Soong*, C. Hay, Y. Liang, E. Carlsen, C. Henard, R. Tirbeni, G. Thaxton, J. Sun  <i>University of Texas Medical Branch, USA</i></p>
17:20-17:35	<p><b>[B3.5] Innovative polymeric adjuvant for PCV2 vaccination</b>  F. Bertrand<sup>1</sup>, J. Ben Arous<sup>2</sup>, J. Gaucheron<sup>2</sup>, S. Sunwoo<sup>3</sup>, Y.S. Lyoo<sup>3</sup>, O.A. Verkhovsky<sup>4</sup> and L. Dupuis<sup>2</sup>  <sup>1</sup><i>SEPPIC China, 580 West Nan Jing Road, Shanghai 200041, China</i> <sup>2</sup><i>SEPPIC, 22 Terrasse Bellini, Paris La Défense, 92806 Puteaux Cedex, France</i> <sup>3</sup><i>Veterinary Immunopathology Lab, College of Veterinary Medicine, Konkuk University, Seoul, South Korea</i> <sup>4</sup><i>“Diagnostic and Prevention Research Institute for Human and Animal Diseases”, Moscow, Russia</i></p>	<p><b>[B4.5] Development of a Chikungunya Vaccine Utilizing the Eilat Virus Platform</b>  J.H. Erasmus*<sup>1</sup>, F. Nasar<sup>3</sup>, G. Leal<sup>1</sup>, J. Kaelber<sup>2</sup>, W. Chiu<sup>2</sup>, V. Popov<sup>1</sup>, D. Kim<sup>4</sup>, H. Luo<sup>1</sup>, T. Wang<sup>1</sup>, S.C. Weaver<sup>1</sup>  <sup>1</sup><i>University of Texas Medical Branch, USA,</i>  <sup>2</sup><i>Baylor College of Medicine, USA,</i> <sup>3</sup><i>U.S. Army Medical Research Institute of Infectious Diseases, USA,</i> <sup>4</sup><i>University of Alabama, USA</i></p>
17:35-17:50	<p><b>[B3.6] TLR9 and STING Agonists Synergistically Induce Innate and Adaptive Type-II IFN</b>  B. Temizoz*<sup>1</sup>, E. Kuroda<sup>1</sup>, K. Ohata<sup>1</sup>, N. Jonai<sup>2</sup>, K. Ozasa<sup>2</sup>, K. Kobiyama<sup>2</sup>, T. Aoshi<sup>2</sup>, K.J. Ishii<sup>1,2</sup>  <sup>1</sup><i>Osaka University, Japan,</i> <sup>2</sup><i>National Institute of Biomedical Innovation, Japan</i></p>	<p><b>[B4.6] A two-component DNA-prime/protein-boost vaccination strategy for eliciting long-term, protective t cell immunity against <i>Trypanosoma cruzi</i></b>  S. Gupta, N.J. Garg*, <i>University of Texas Medical Branch, USA</i></p>
17:50-18:05	<p><b>[B3.7] A novel approach to differentiate antibody response from vaccination and natural infection of flavivirus.</b>  D-Y. Chao<sup>1</sup>, J.U. Galula<sup>1</sup>, G-J. J. Chang<sup>2</sup>  <sup>1</sup><i>National Chung-Hsing University, Taiwan,</i>  <sup>2</sup><i>Centers for Disease Control and Prevention, USA</i></p>	<p><b>[B4.7] A multivalent Ebola GP DNA vaccine induces seroconversion after a single immunization and protects against lethal Guinea-Makona 2014 virus challenge in non-human primates.</b>  A. Patel<sup>1</sup>, E.L. Resuchel<sup>1</sup>, K.A. Kraynyak<sup>2</sup>, T. Racine<sup>3</sup>, J. Walters<sup>1</sup>, J. Audet<sup>3,4</sup>, M. Karupiah<sup>1</sup>, D.J. Shedlock<sup>1</sup>, A. Bello<sup>3</sup>, G. Soule<sup>3</sup>, K.N. Tran<sup>2</sup>, J. Yan<sup>2</sup>, M. Yang<sup>2</sup>, A. Khan<sup>2</sup>, K. Tierney<sup>3</sup>, X. Qiu<sup>3</sup>, G.P. Kobinger<sup>1,3,4</sup>, N.Y. Sardesai<sup>2</sup>, D.B. Weiner<sup>1</sup>.  <sup>1</sup><i>University of Pennsylvania, USA</i>  <sup>2</sup><i>Inovio Pharmaceuticals, Plymouth Meeting, USA</i>  <sup>3</sup><i>Public Health Agency of Canada, Canada</i>  <sup>4</sup><i>University of Manitoba, Canada</i></p>
18:05-19:00	<p><b>Welcome Drinks Reception and Poster Session 1</b>  <i>Crystal Ballroom Foyer</i></p>	<p><b>Sponsored by</b></p> 

## Monday, 19 October 2015

08:30-10:35	Plenary Session 1: Vaccines against Viral Pathogens: Session Chairs: Gavin Smith & Adolfo Garcia-Sastre <i>Crystal Ballroom 1&amp;2</i>	
08:30-08:55	<p><b>[PLN1.1] The phylodynamics of H1N1/2009 influenza: From pandemic to seasonal influenza</b> Y.C.F. Su<sup>1</sup>, J. Bahl<sup>1,2</sup>, U. Joseph<sup>1</sup>, K.M. Butt<sup>1</sup>, H.A. Peck<sup>3</sup>, E.S.C. Koay<sup>4</sup>, L.L.E. Oon<sup>5</sup>, I.G. Barr<sup>3</sup>, D. Vijaykrishna<sup>1,3</sup>, G.J.D. Smith<sup>*1,3</sup> <sup>1</sup>Duke-NUS Graduate Medical School, Singapore, <sup>2</sup>The University of Texas, USA, <sup>3</sup>World Health Organisation Collaborating Centre for Reference and Research on Influenza, Australia, <sup>4</sup>National University Hospital, Singapore, <sup>5</sup>Singapore General Hospital, Singapore, <sup>6</sup>National University of Singapore, Singapore, <sup>7</sup>Duke University, USA</p>	
08:55-09:20	<p><b>[PLN1.2] Development of the Sanofi Pasteur dengue vaccine: Early development, efficacy studies &amp; next steps</b> B. Guy*, O. Briand, J. Lang, M. Saville, N. Jackson, <i>Sanofi Pasteur, France</i></p>	
09:20-09:35	<p><b>[PLN1.3] Deep sequencing of the Yellow Fever vaccine strain 17D reveals low diversity compared to wild-type parent Asibi virus and population stability for primary and secondary seed lots of 17D vaccine</b> A.D.T. Barrett*, A. Beck, N. Collins, S.G. Widen, T. Wood, J.K. Thompson, <i>University of Texas Medical Branch, USA</i></p>	
09:35-09:50	<p><b>[PLN1.4] Immunization with a single recombinant hepatitis C virus envelope protein elicits pan-genotypic neutralizing antibodies in macaques and confers protection against viral challenge in mice</b> D. Li<sup>1</sup>, M. von Schaewen<sup>2</sup>, X. Wang<sup>1</sup>, W. Tao<sup>1</sup>, Y. Zhang<sup>1</sup>, L. Li<sup>1</sup>, B. Heller<sup>2</sup>, A. Ploss<sup>2</sup>, J. Zhong<sup>1</sup>, <i>et al.</i> <sup>1</sup>Institut Pasteur of Shanghai, China, <sup>2</sup>Princeton University, USA</p>	
09:50-10:05	<p><b>[PLN1.5] Development of a novel genetically stable live-attenuated respiratory syncytial virus (RSV) vaccine that provides enhanced immunogenicity and thermal stability</b> C.C. Stobart<sup>*1,2</sup>, C.A. Rostad<sup>1,2</sup>, R.J. Pickles<sup>3</sup>, Z. Ke<sup>1,6</sup>, J. Meng<sup>1,2</sup>, K. Sakamoto<sup>4</sup>, A.L. Hotard<sup>1,2</sup>, S. Lee<sup>1,2</sup>, P.A. Piedra<sup>5</sup>, B.E. Gilbert<sup>5</sup>, E.R. Wright<sup>1,2</sup>, M.L. Moore<sup>1,2</sup> <sup>1</sup>Emory University School of Medicine, USA, <sup>2</sup>Children's Healthcare of Atlanta, USA, <sup>3</sup>University of North Carolina, USA, <sup>4</sup>University of Georgia, USA, <sup>5</sup>Baylor College of Medicine, USA, <sup>6</sup>Georgia Institute of Technology, USA</p>	
10:05-10:20	<p><b>[PLN1.6] Recombinant adeno-vaccine expressing Enterovirus 71-like particles against hand, foot, and mouth disease</b> Y.H. Chow<sup>*1</sup>, Y.L. Tsou<sup>1,1</sup> <i>National Health Research Institutes, Taiwan, <sup>2</sup>China Medical University, Taiwan</i></p>	
10:20-10:35	<p><b>[PLN1.7] Generation of CAVA poliovirus strains for the development of an affordable and safe next generation inactivated poliovirus vaccine</b> B.P. Sanders*, I. de los Rios, V. van Hoek, D.E. Matas, J. Custers, H. Schuitemaker <i>Janssen Infectious Diseases and Vaccines, The Netherlands</i></p>	
10:35-11:00	Refreshment Break <i>Crystal Ballroom Foyer</i>	
11:00-12:40	Breakout Session 5: Therapeutic Vaccines: Session Chairs: Ian Frazer and Randy Albrecht <i>Crystal Ballroom 1</i>  Sponsored by	Breakout Session 6: Vaccine Delivery: Session Chairs: Anna-Lise Williamson & Heather Wilson <i>Crystal Ballroom 2</i>
11:00-11:20	<p><b>[B5.1] Immunological interventions for anogenital viral infections</b> I.H. Frazer, <i>Translational Research Institute, Australia</i></p>	<p><b>[B6.1] Dissolving polymer microneedle immunization with trivalent inactivated influenza vaccine</b> E.V. Vassilieva<sup>1</sup>, H. Kalluri<sup>2</sup>, D. McAllister<sup>2</sup>, M. T. Taherbhai<sup>1</sup>, E.S. Esser<sup>1</sup>, W.P. Pewin<sup>2</sup>, J.A. Pulit-Penalzo<sup>1,3</sup>, M.R. Prausnitz<sup>2</sup>, R.W. Compans<sup>1</sup>, I. Skountzou<sup>*1</sup> <sup>1</sup>Emory University School of Medicine, USA, <sup>2</sup>Georgia Institute of Technology, USA, <sup>3</sup>Centers for Disease Control, USA</p>
11:20-11:40	<p><b>[B5.2] The optimization and development of a novel therapeutic DNA vaccine</b> H-T. Jin, <i>BioDion, Inc, Republic of Korea</i></p>	<p><b>[B6.2] Capripoxviruses as host-restricted vaccine vectors</b> K. Offerman<sup>1</sup>, N. Douglass<sup>1</sup>, A. Deffur<sup>1</sup>,</p>

		R.J. Wilkinson <sup>1</sup> , A-L Williamson* <sup>1</sup> <sup>1</sup> University of Cape Town, South Africa, <sup>2</sup> Groote Schuur Hospital, South Africa
11:40-11:55	<b>[B5.3] Human monoclonal antibody 100F4 cross-neutralizes and cross-protects newly emerging highly pathogenic avian influenza H5N8 virus <i>in vivo</i>.</b> H. Ren <sup>1*</sup> , G. Wang <sup>1</sup> , S. Wang <sup>1</sup> , P. Buchy <sup>2</sup> , G. Cheng <sup>3</sup> , V. Deubel <sup>2</sup> , and P. Zhou <sup>1</sup> . <sup>1</sup> Chinese Academy of Sciences, China, <sup>2</sup> Institut Pasteur in Cambodia, Cambodia, <sup>3</sup> University of California Los Angeles, USA	<b>[B6.3] <i>In vivo</i> visualization of a protective nanovaccine formulation</b> A. Seth, N. Wibowo, L.H.L. Lua, A.P.J. Middelberg* The University of Queensland, Australia
11:55-12:10	<b>[B5.4] Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma</b> M. Tagliamonte <sup>1</sup> , A. Petrizzo <sup>1</sup> , M. Napolitano <sup>1</sup> , C. Arra <sup>1</sup> , P. Maiolino <sup>1</sup> , M. Tornesello <sup>1</sup> , L. Aurisicchio <sup>2</sup> , G. Ciliberto <sup>1</sup> , F.M. Buonaguro <sup>1</sup> , L. Buonaguro* <sup>1</sup> <sup>1</sup> IRCCS, Italy, <sup>2</sup> Takis, S.R.L., Italy	<b>[B6.4] DNA-launched attenuated RNA vaccines</b> I.S. Lukashevich* <sup>1</sup> , I. Tretyakova <sup>2</sup> , P. Pushko <sup>2</sup> <sup>1</sup> University of Louisville, USA, <sup>2</sup> Medigen, Inc, USA
12:10-12:25	<b>[B5.5] A novel therapeutic vaccine against tuberculosis in the monkey model, preclinical study and clinical trial</b> M. Okada* <sup>1</sup> , T. Nakajima <sup>2</sup> , Y. Kaneda <sup>3</sup> , Y. Inoue <sup>1</sup> , K. Tomono <sup>3</sup> , A. Kumanogoh <sup>3</sup> , K. Tsuyuguchi <sup>1</sup> , S. Syoji <sup>4</sup> , A. Mikami <sup>5</sup> , T. Saito <sup>6</sup> et al <sup>1</sup> National Hospital Organization Kinki-chuo Chest Medical Center, Japan, <sup>2</sup> Genomidea Co., Japan, <sup>3</sup> Osaka University, Japan, <sup>4</sup> NHO Tokyo Hospital, Japan, <sup>5</sup> Tokai University, Japan, <sup>6</sup> NHO Ibaraki-higashi Hospital, Japan	<b>[B6.5] Parainfluenza virus 5 (PIV5) is a promising live vector for vaccine development</b> B. He, University of Georgia, USA
12:25-12:40	<b>[B5.6] Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease</b> H-F. Tseng, Y. Luo, J. Shi, S. Tartof, J. Sim, S. Jacobsen, Kaiser Permanente Southern California, USA	<b>[B6.6] Measles and Rubella Vaccination Using a Microneedle Patch</b> M.L. Collins* <sup>1</sup> , J.C. Joyce <sup>2</sup> , M. Chen <sup>1</sup> , P.A. Rota <sup>1</sup> , M.R. Prausnitz <sup>2,1</sup> Centers for Disease Control and Prevention, USA, <sup>2</sup> Georgia Institute of Technology, USA
12:40-14:00	<b>Lunch</b> Crystal Ballroom Foyer	
13:00-14:00	<b>Vaccine Author Workshop: How to get published!</b> Greg Poland, Editor-in-Chief of <i>Vaccine</i> and Alina Hensloot, Publisher of <i>Vaccine</i> Crystal Ballroom 1	
14:00-15:00	<b>ISV Annual General Meeting (open)</b> Crystal Ballroom 2	
15:00-16:00	<b>Refreshments and Poster Session 2</b> Crystal Ballroom Foyer	
16:00-18:30	<b>Breakout Session 7: Bacterial Vaccines</b> Session Chairs: Florian Marks and Linda Klavinskis Crystal Ballroom 1	<b>Breakout Session 8: Vaccines for Respiratory Pathogens</b> Session Chairs: Paul Zhou and Anders Fomsgaard Crystal Ballroom 2
16:00-16:20	<b>[B7.1] Invasive <i>Salmonella</i> infections in Africa and implications for vaccination programs</b> F. Marks, International Vaccine Institute, Korea	<b>[B8.1] Hemagglutinin (HA)-based "universal" vaccine development against influenza viruses</b> P. Zhou, Chinese Academy of Sciences, China
16:20-16:40	<b>[B7.2] Next generation protein based <i>Streptococcus pneumoniae</i> vaccines</b> M.E. Pichichero, Rochester General Hospital Research Institute, USA	<b>[B8.2] Polyvalent influenza-A DNA vaccine for pigs and humans</b> A. Fomsgaard* <sup>1</sup> , M. Borggren <sup>1</sup> , J. Nielsen <sup>1</sup> , I. Karlsson <sup>1</sup> , J. Williams <sup>2</sup> <sup>1</sup> Statens Serum Institut, Denmark, <sup>2</sup> Nature Technology Corporation, USA

16:40-17:00	<p><b>[B7.3] Deletion of specific small RNAs enhances the vaccine cross-protection of an <i>rfaH</i> mutant of <i>Salmonella enterica</i> serovar Typhimurium</b>  B.L. Bearson*, S.M.D. Bearson. <i>USDA, ARS, USA</i></p>	<p><b>[B8.3] Better influenza vaccines: looking beyond the viral hemagglutinin</b>  X. Saelens<sup>1,2</sup>  <sup>1</sup><i>VIB, Belgium, <sup>2</sup>Ghent University, Belgium</i></p>
17:00-17:15	<p><b>[B7.4] Induction of cross-reactive multifunctional CD4+T cells in healthy volunteers immunized with the live oral typhoid vaccine Ty21a</b>  R. Wahid*, S. Fresnay, M.M. Levine, M.B. Szein  <i>University of Maryland School of Medicine, USA</i></p>	<p><b>[B8.4] Design and characterization of a COBRA hemagglutinin vaccine for H1N1 influenza viruses.</b>  D.M. Carter*<sup>1</sup>, C.A. Darby<sup>1</sup>, C.J. Crevar<sup>2</sup>, B.C. Lefoley<sup>1</sup>, T. Alefantis<sup>2</sup>, H. Kleanthous<sup>2</sup>, T.M. Ross<sup>1</sup>  <sup>1</sup><i>University of Georgia, USA, <sup>2</sup>Sanofi-Pasteur, USA</i></p>
17:15-17:30	<p><b>[B7.5] Recombinant ESAT-6-like proteins provoke protective immune responses against invasive <i>Staphylococcus aureus</i> disease in a murine model</b>  <sup>1,2</sup>BaoZhong Zhang, <sup>1</sup>YanHong Hua, <sup>1</sup>Bin Yu, <sup>2</sup>Candy ChoiYi Lau, <sup>2</sup>JianPiao Cai, <sup>1</sup>SongYue Zheng, <sup>2</sup>WingCheong Yam, <sup>2</sup>Richard Yi-Tsun Kao, <sup>2</sup>Konghung SZE, <sup>2</sup>Bo-Jian Zheng, <sup>2</sup>Kwok-Yung Yuen  <sup>1</sup>Jian-Dong Huang  <sup>1</sup><i>Department of Biochemistry, The University of Hong Kong, Hong Kong, <sup>2</sup>Department of Microbiology, The University of Hong Kong</i></p>	<p><b>[B8.5] Influenza virus hemagglutinin stalk-based immunity in ferrets</b>  F. Krammer<sup>1</sup>, R. Nachbagauer<sup>1,2</sup>, P. Palese<sup>1</sup>, A. García-Sastre<sup>1</sup>, R.A. Albrecht*<sup>1</sup>  <sup>1</sup><i>Icahn School of Medicine, USA, <sup>2</sup>University of Vienna, Austria</i></p>
17:30-17:45	<p><b>[B7.6] Protection against influenza-bacterial co-infection by M2e universal influenza vaccine.</b>  I. Chrostopoulou, W. Fiers, X. Saelens  <sup>1</sup><i>VIB, Belgium, <sup>2</sup>Ghent University, Belgium</i></p>	<p><b>[B8.6] Broad immune response induced by plant-made influenza VLP vaccines</b>  N. Landry<sup>1</sup>, S. Trépanier<sup>1</sup>, E. Aubin<sup>1</sup>, S. Pillet<sup>1,2</sup>, and B.J. Ward<sup>1,2</sup>  <sup>1</sup><i>Medicago Inc., Quebec, Canada; <sup>2</sup>Research Institute of the McGill University Health Centre University, Canada</i></p>
17:45-18:00	<p><b>[B7.7] Multiple non-vaccine serotypes of streptococcus pneumoniae emerge during the 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccination - Rochester, NY - 2006-2014</b>  J.R. Casey*<sup>1</sup>, R. Kaur<sup>2</sup>, M.E. Pichichero<sup>1</sup>  <sup>1</sup><i>Legacy Pediatrics, USA, <sup>2</sup>Rochester General Hospital Research Institute, USA</i></p>	<p><b>[B8.7] Bioluminescent influenza A viruses for evaluating influenza virus vaccine</b>  Weiqi PAN<sup>1</sup>, Liqiang FENG<sup>2</sup>, Chufang LI<sup>1</sup>, Ling CHEN<sup>1,2</sup>  <sup>1</sup><i>State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou; <sup>2</sup>, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China</i></p>
18:00-18:15	<p><b>[B7.8] Affordable Conjugate Vaccines: Efficient chemistry and Low Cost CRM<sub>197</sub> Carrier Protein.</b>  A. Lees*<sup>1</sup>, S. Jain<sup>2</sup> &amp; N. Oganessian<sup>1</sup>  <sup>1</sup><i>Fina Biosolutions LLC., USA <sup>2</sup>Novo Biosolutions Inc., USA</i></p>	<p><b>[B8.8] A nanogel influenza vaccine conferred better protection against influenza virus infection</b>  Q. Wang<sup>1</sup>, W. Pan<sup>2</sup>, C. Li<sup>2</sup>, L. Chen*<sup>1,2</sup>  <sup>1</sup><i>Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, China, <sup>2</sup>Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China</i></p>
18:15-18:30	<p><b>[B7.9] Serotype distribution of <i>Streptococcus pneumoniae</i> in children with invasive diseases in Turkey: 2008-2014</b>  M. Ceyhan*<sup>1</sup>, Y. Ozsurekci<sup>1</sup>, N. Gurler<sup>2</sup>, L. Oksuz<sup>2</sup>, S. Aydemir<sup>3</sup>, S. Ozkan<sup>4</sup>, S. Yuksekkaya<sup>5</sup>, M. Keser Emiroglu<sup>6</sup>, M. Gultekin<sup>7</sup>, A. Yaman<sup>8</sup> et al.  <sup>1</sup><i>Hacettepe University, Turkey, <sup>2</sup>Istanbul University, Turkey, <sup>3</sup>Ege University, Turkey, <sup>4</sup>Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital, Turkey, <sup>5</sup>Konya Training and Research Hospital, Turkey, <sup>6</sup>Selcuk University, Turkey, <sup>7</sup>Akdeniz University, Turkey, <sup>8</sup>Cukurova University, Turkey</i></p>	<p><b>[B8.9] Broadly neutralizing antibodies induced by multivalent inactivated rhinovirus</b>  S. Lee*<sup>1,2</sup>, M.T. Nguyen<sup>1</sup>, M.G. Currier<sup>1,2</sup>, M.L. Moore<sup>1,2</sup>  <sup>1</sup><i>Emory University Department of Pediatrics, USA, <sup>2</sup>Children's Healthcare of Atlanta, USA</i></p>

19:15	Depart the front of the Hotel to go to the Gala Dinner (ticket holders only)	
19:30-23:00	Congress Gala Dinner (ticket holders only)	
<b>Tuesday, 20 October 2015</b>		
08:00-08:30	Congress Registration	
08:30-10:30	Plenary Session 2: Clinical Trials: Session Chairs: Shan Lu and Allan Saul <i>Crystal Ballroom 1&amp;2</i>	
08:30-08:50	<b>[PLN2.1] Clinical proof-of-concept of SBVGH Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) vaccine administered by intramuscular route</b> A. Saul, <i>Novartis Vaccines for Global Health, Italy</i>	
08:50-09:10	<b>[PLN2.2] Sub-Saharan Africa's contribution to HIV vaccine and cure research: a case study</b> H.N. Kibuuka, <i>Makerere University Walter Reed Project, Uganda</i>	
09:10-09:30	<b>[PLN2.3] Overview of the effectiveness and safety of the oral human rotavirus vaccine, rotarix; 10 years after its introduction: delivering the promise of protection against rotavirus diarrhoea.</b> B. Benninghoff, <i>GSK Global Medical Affairs, Belgium</i>	
09:30-09:45	<b>[PLN2.4] Faster, Bigger, Better: Current Status and Future Challenges in Post-Licensure Vaccine Safety Assessment</b> W.L. Straus, <i>MSD (Merck &amp; Co., Inc.), USA</i>	
09:45-10:00	<b>[PLN2.5] Post hoc analysis of a randomized double-blind trial of correlation of low varicella zoster vaccine responses by concomitant administration of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes</b> A. Hata* <sup>1</sup> , T. Ishioka <sup>2,3</sup> , K. Oishi <sup>2</sup> , T. Katayama <sup>4</sup> , T. Ohkubo <sup>5</sup> <sup>1</sup> The Tazuke Kofukai Medical Research Institute, Japan, <sup>2</sup> National Institute of Infectious Diseases, Japan, <sup>3</sup> Takasaki General Public Health Center, Japan, <sup>4</sup> Himeji Dokkyo University, Japan, <sup>5</sup> Teikyo University School of Medicine, Japan	
10:00-10:15	<b>[PLN2.6] Safety and immunogenicity of recombinant acellular pertussis vaccine (ap) and combined tetanus, diphtheria, recombinant acellular pertussis (tdap) vaccine in 18-35 years old healthy adults in Thailand</b> C. Sirivichayakul* <sup>1</sup> , P. Chanthavanich <sup>1</sup> , K. Limkittikul <sup>1</sup> , C-A. Siegrist <sup>2</sup> , J. Petre <sup>3</sup> , W. Wijagkanalan <sup>3</sup> , P. Chinwangso <sup>3</sup> , M. Chauhan <sup>3</sup> , H-T. Pham <sup>3</sup> , S. Viviani <sup>3</sup> <sup>1</sup> Mahidol University, Thailand, <sup>2</sup> Medicine University of Geneva, Switzerland, <sup>3</sup> BioNet-Asia Co., Thailand	
10:15-10:30	<b>[PLN2.7] Acquisition of vaginal colonization with group B Streptococcus in pregnant women induces higher antibody responses to protein antigens than rectal colonization</b> S. Dzanibe* <sup>1,2</sup> , P.V. Adrian <sup>1,2</sup> , G. Kwatra <sup>1,2</sup> , S.Z. Kimaro-Mlacha <sup>1,2</sup> , S.A. Madhi <sup>2,3</sup> <sup>1</sup> University of the Witwatersrand, South Africa, <sup>2</sup> Respiratory and Meningeal Pathogen Research Unit, South Africa, <sup>3</sup> National Institute of Communicable Diseases, South Africa	
10:30-11:00	Refreshment Break <i>Crystal Ballroom Foyer</i>	
11:00-12:55	Breakout Session 9: Vaccine Policy, Production, and Manufacturing Supported by Japanese Society for Vaccines Session Chairs: Ken Ishii and Steve Black <i>Crystal Ballroom 1</i>	Breakout Session 10: Mucosal Vaccination and Immunity Session Chairs: Hideki Hasegawa and Bin Wang <i>Crystal Ballroom 2</i>
11:00-11:20	<b>[B9.1] Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap"</b> A. Saitoh, <i>Niigata University Graduate School of Medical and Dental Sciences, Japan</i>	<b>[B10.1] Development of intranasal inactivated influenza vaccine and immune system induced by the vaccine</b> H.H. Hasegawa, <i>National Institute of Infectious Diseases, Japan</i>
11:20-11:40	<b>[B9.2] Achievement of measles elimination in Japan, March 2015</b> T. Sunagawa, <i>National Institute of Infectious Diseases, Japan</i>	<b>[B10.2] Oral CTL vaccine against HIV-1 using a CTP-integrated sabin 1 poliovirus-derived mucosal vector RPS-VAX system.</b> M-H. Kang*, Y-J. Park, J. Lee, S-S. Han, M-S. Cha, E. Lee, Y-S. Bae, <i>Sungkyunkwan University, Republic of Korea</i>
11:40-11:55	<b>[B9.3] Budget impact of introducing inactivated poliomyelitis vaccine (IPV): a case study of child immunization program of India</b>	<b>[B10.3] Tablet vaccine platform elicits neutralizing antibodies without impact on preexisting immunity</b> S.N. Tucker*, J.D. Lindbloom, L. Kim, J. Martinez, K. Hodgson, C.D. Scallan, D. Liebowitz

	M.M. Khan* <sup>1</sup> , S. Sharma <sup>2</sup> , B. Tripathi <sup>4</sup> , F.P. Alvarez <sup>3,1</sup> <i>University of South Carolina, USA</i> , <sup>2</sup> <i>Sanofi Pasteur, India</i> , <sup>3</sup> <i>Sanofi Pasteur, France</i> , <sup>4</sup> <i>Independent Consultant, India</i>	Vaxart, Inc., USA
11:55-12:10	<b>[B9.4] Novel adjuvant L-pampo and its applications</b> H.J. Jo, S.K. Jeong, S.H. Baek, E.J. Jung, B.M. Kim, B.C. Ahn, J.S. Yum <i>R&amp;D Center, CHA Vaccine Institute, Republic of Korea</i>	<b>[B10.4] Safety of rotavirus vaccine for very low birth weight infants in NICU</b> F. Hattori* <sup>1</sup> , K. Sugata <sup>1</sup> , M. Ihira <sup>2</sup> , H. Hiramatsu <sup>3</sup> , R. Suzuki <sup>3</sup> , K. Taniguchi <sup>1</sup> , S. Yamada <sup>3</sup> , T. Yoshikawa <sup>1</sup> <sup>1</sup> <i>Fujita Health University School of Medicine, Japan</i> , <sup>2</sup> <i>Fujita Health University, Japan</i> , <sup>3</sup> <i>Fujita Health University Hospital, Japan</i>
12:10-12:25	<b>[B9.5] Introducing non-traditional vaccines in Indonesia: rotavirus and hepatitis A as reference cases</b> A.A. Suwantika* <sup>1,2</sup> , K. Lestari <sup>1</sup> , M.J. Postma <sup>2</sup> <sup>1</sup> <i>Universitas Padjadjaran, Indonesia</i> , <sup>2</sup> <i>University of Groningen, The Netherlands</i>	<b>[B10.5] Neutrophils regulation of mucosal IgA responses to experimental sublingual vaccines</b> J. Jee, E. Kim, E. Cormet-boyaka, T.L. Martin, H.E. Steiner, P.N. Boyaka* <i>The Ohio State University, USA</i>
12:25-12:40	<b>[B9.6] Estimating resource needs for achieving adult vaccination targets in the USA</b> M.M. Khan* <sup>1</sup> , V. Heboyan <sup>2</sup> <sup>1</sup> <i>University of South Carolina, USA</i> , <sup>2</sup> <i>Georgia Regents University, USA</i>	<b>[B10.6] Development of liposome-based vaccine formulations to enhance the longevity of vaccine-induced immunity against foot-and-mouth disease virus</b> R.O. Braun* <sup>1,4</sup> , L. Brunner <sup>2</sup> , G. Auray <sup>1</sup> , A. Baumann <sup>1</sup> , O. García-Nicolás <sup>1</sup> , S. Python <sup>1</sup> , B. Zumkehr <sup>1</sup> , M.H. Stoffel <sup>3</sup> , C. Barnier-Quer <sup>2</sup> , A. Summerfield <sup>1</sup> et al <sup>1</sup> <i>Institute of Virology and Immunology, Switzerland</i> , <sup>2</sup> <i>University of Lausanne, Switzerland</i> , <sup>3</sup> <i>University of Bern, Switzerland</i> , <sup>4</sup> <i>University of Bern, Switzerland</i>
12:40-12:55	<b>[B9.7] The native confirmation of Influenza haemagglutinin as a surrogate for vaccine potency.</b> A. Farnsworth*, M. Lemieux, S. Li. <i>Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Canada</i>	<b>[B10.7] Vaccine potential of intranasal attenuated influenza virus vector expressing two <i>M. tuberculosis</i> antigens: preclinical and phase 1 clinical study results</b> M. Stukova* <sup>1</sup> , A-P. Shurygina <sup>1</sup> , B. Khairullin <sup>2</sup> , T. Abildaev <sup>3</sup> , J. Buzitskaya <sup>1</sup> , M. Kassenov <sup>2</sup> , N. Zabolotnyh <sup>4</sup> , T. Vinogradova <sup>4</sup> , A. Sansyrbay <sup>2</sup> , O. Kiselev <sup>1</sup> et al. <sup>1</sup> <i>Research Institute of influenza, Russia</i> , <sup>2</sup> <i>Research Institute for Biological Safety Problems, Kazakhstan</i> , <sup>3</sup> <i>National Center for Tuberculosis Problem, Kazakhstan</i> , <sup>4</sup> <i>Saint-Petersburg Research Institute of Phthisiopulmonology, Russia</i>
12:55-14:00	<b>Lunch and Poster Viewing</b> <i>Crystal Ballroom Foyer</i>	
13:00-14:00	<b>Career Development Workshop: Identifying and Achieving your Dream Job</b> <i>Crystal Ballroom 1</i>	
14:00-14:20	<b>Edward Jenner Poster Prize Ceremony</b>	
14:20-15:00	<b>Plenary Session 3: Closing Keynotes: Session Chairs: Ted M. Ross and Joon Haeng Rhee</b>	
14:20-14:40	<b>[PLN3.1] The costs and effectiveness of large pre-licensure safety studies: time for a new paradigm</b> S. Black <i>University of Cincinnati Children's Hospital, USA</i>	
14:40-15:00	<b>[PLN3.2] Universal influenza vaccine approach: options and obstacles</b> Y.H. Jang <sup>1</sup> , B.L. Seong* <sup>1,2</sup> <sup>1</sup> <i>Life Science &amp; Biotechnology</i> <sup>2</sup> <i>Vaccine Translational Research Center, Yonsei University, Republic of Korea</i>	
15:00-15:15	<b>Closing Summary: Margaret Liu, Joon Haeng Rhee, and Ted M. Ross, Congress Co-Chairs</b>	